Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bone Marrow Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2011.15PMID 21358688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Graft-Versus-Host Disease

  2016cited by this paper
• Interactive diagnostics in the indication to allogeneic SCT in AML

  2009cited by this paper
• Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

  2009cited by this paper
• Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

  2009cited by this paper
• Current status of blood and marrow transplantation for patients with AML

  2008cited by this paper
• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

  2008cited by this paper
• Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.

  2008cited by this paper
• Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

  2008cited by this paper
• Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

  2007cited by this paper
• Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

  2007cited by this paper
• Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

  2007cited by this paper
• Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

  2006cited by this paper
• Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.

  2006cited by this paper
• Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.

  2005cited by this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cited by this paper
• A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

  2004cited by this paper
• Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

  2003cited by this paper
• Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases

  2002cited by this paper
• Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients

  2001cited by this paper
• Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

  2000cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

  2000cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission.

  1995cited by this paper
• Graft-versus-leukemia reactions after bone marrow transplantation.

  1990cited by this paper

• Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukemia and myelodysplastic syndrome: validation of current recommendations and proposal of a modified outcome assessment

  2025cites this paper
• Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT

  2025cites this paper
• Case Report: Decitabine and venetoclax sequentially followed by FLAG-Ida and venetoclax with immediate allogeneic stem cell transplantation in newly diagnosed acute myeloid leukemia with chromosome 3 inversion/MECOM rearrangement

  2025cites this paper
• Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

  2024cites this paper
• On Behalf of the SFGM-TC: Prophylactic Donor Lymphocyte Infusion in Patients Treated with Allogeneic Stem-Cell Transplantation for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

  2023cites this paper
• Maintenance therapy in acute myeloid leukemia: advances and controversies

  2023cites this paper
• Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.

  2022cites this paper
• Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse

  2022cites this paper
• Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia

  2021cites this paper
• Time‐dependent analysis of adoptive immunotherapy following sequential FLAMSA‐reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high‐risk myeloid neoplasia

  2021cites this paper
• [Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects].

  2021cites this paper
• Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.

  2020influential citation
• Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning—a matched pair analysis

  2019cites this paper
• Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.

  2018cites this paper
• Allogeneic hematopoietic cell transplantation in chemotherapy‐induced aplasia in children with high‐risk acute myeloid leukemia or myelodysplasia

  2018cites this paper
• Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

  2018cites this paper
• The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.

  2018cites this paper
• Efficacy of Chemotherapy in Acute Leukemia Patients Resistant to Previous Standard Treatment According to the Series Measurement of WT1 Gene Expression

  2018cites this paper
• Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia

  2017cites this paper
• Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia

  2017influential citation
• Chromosome Abnormalities and Hematopoietic Stem Cell Transplantation in Acute Leukemias

  2017cites this paper
• Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT

  2017cites this paper
• FLAMSA reduced‐intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission

  2016cites this paper
• Hematopoietic stem cell transplantation for patients with AML in first complete remission.

  2016cites this paper
• Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

  2016cites this paper
• Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

  2016cites this paper
• Correlation of somatic mutations with outcome after FLAMSA‐busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes

  2016cites this paper
• Complex Chromosomal Aberrations in Patients with Post-Transplantation Relapses of Acute Leukemias: Clinical and Theoretical Aspects

  2015cites this paper
• ADVANCES IN ACUTE MYELOID LEUKEMIA Hematopoietic stem cell transplantation for patients with AML in first complete remission

  2015cites this paper
• Ostre białaczki szpikowe – leczenie postaci nawrotowych i opornych

  2015cites this paper
• Reduced-intensity conditioned allogeneic SCT in adults with AML

  2015cites this paper
• Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

  2015influential citation
• Profiles of Activation, Differentiation–Markers, or &bgr;-Integrins on T Cells Contribute to Predict T Cells’ Antileukemic Responses After Stimulation With Leukemia-derived Dendritic Cells

  2014cites this paper
• Immunologic Outcomes of Allogeneic Stem Cell Transplantation: Graft-Versus-Host and Graft-Versus-Leukemia Responses and Implications for Future Therapy

  2014cites this paper
• To establish the role of mutations in c-KIT tyrosine kinase in the pathogenesis and therapy of core-binding factor-related acute myeloid leukaemia (AML)

  2014cites this paper
• Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia

  2013cites this paper
• Pharmacological methods to reduce disease recurrence.

  2013cites this paper
• Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse

  2013cites this paper
• Terapia celowana i transplantacja komórek krwiotwórczych szansą na wyleczenie chorych z ostrą białaczką szpikową

  2013cites this paper
• Novel approaches to the treatment of acute myeloid leukemia.

  2011cites this paper
• Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation

  year unknowncites this paper